A Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB037 in Subjects With Mild to Moderate Alzheimer's Disease.
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2015
At a glance
- Drugs Aducanumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Biogen
- 12 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Jul 2013 Interim results (n=48) presented at the 2013 Alzheimer's Association International Conference .
- 14 Jul 2013 Planned number of patients changed from 48 to 56.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History